| |
 |
|
|
Inventor: Ruhter; Gerd
Address: Hamburg, DE
No. of patents: 13
Patents:
| Patent Number |
Title Of Patent |
Date Issued |
| 6756403 |
Methods for producing chiral chromones, chromanes, amino substituted chromanes and intermediates |
June 29, 2004 |
| Disclosed are process steps and novel processes for producing chromane compositions enriched in at least one (2R or 2S) enantiomer, preferably chroman-2-yl carboxylic acid compounds and chroman-2-yl carboxylic acid esters which are intermediates for producing platelet aggregation inh |
| 6693109 |
Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation |
February 17, 2004 |
| This invention relates to certain spirocyclic compounds substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation. |
| 6528534 |
Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation |
March 4, 2003 |
| This invention relates to certain spirocyclic compounds substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation. |
| 6448269 |
Glycoprotein IIb/IIIa antagonists |
September 10, 2002 |
| This invention relates to certain bicyclic compounds having a nucleus formed of two fused six membered rings, for example, benzopyran, isoquinoline, isoquinolone, tetrahydronaphthalene, dihydronaphthalene, or tetralone, substituted with both basic and acidic functionality, which are |
| 6410562 |
Hypoglycemic imidazoline compounds |
June 25, 2002 |
| This invention relates to certain novel imidazoline compounds and analogues thereof, to their use for the treatment of diabetes, diabetic complications, metabolic disorders, or related diseases where impaired glucose disposal is present, to pharmaceutical compositions comprising them |
| 6291469 |
Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation |
September 18, 2001 |
| This invention relates to certain spirocyclic compounds substituted with both basic and acidic functionality, as shown by formula (I): ##STR1##wherein Q, L, A.sub.i, B.sub.j, R.sub.0, R.sub.3, R.sub.10, m, n, p and q are as defined in the disclosure, which are useful in inhibiting of |
| 6020362 |
Glycoprotein IIB IIIA antagonists |
February 1, 2000 |
| This invention relates to certain bicyclic compounds having a nucleus formed of two fused six membered rings, for example, benzopyran, isoquinoline, isoquinolone, tetrahydronaphthalene, dihydronaphthalene, or tetralone, substituted with both basic and acidic functionality, which are |
| 5731324 |
Glycoprotein IIb/IIIa antagonists |
March 24, 1998 |
| This invention relates to certain bicyclic compounds having a nucleus formed of two fused six membered rings, for example, benzopyran, isoquinoline, isoquinolone, tetrahydronaphthalene, dihydronaphthalene, or tetralone, substituted with both basic and acidic functionality, which are |
| 5668152 |
Protein kinase C inhibitors |
September 16, 1997 |
| The present invention discloses compounds that are highly isozyme selective protein kinase C beta-1 and beta-2 isozyme inhibitors. Accordingly, the present invention provides a method of selectively inhibiting protein kinase C isozymes beta-1, and beta-2. As isozyme selective inhibitors |
| 5602137 |
Pyrimidine compounds and their use as pharmaceuticals |
February 11, 1997 |
| Compounds for treating cardiovascular or circulatory disorders of the formula ##STR1## and pharmaceutically acceptable salts thereof wherein R.sup.1, R.sup.2, R.sup.3, R.sup.7, Ar.sup.1, Ar.sup.2, X, Y, and n are defined herein. |
| 5602136 |
Pyrimidine compounds and their use as pharmaceuticals |
February 11, 1997 |
| Compounds having the formula ##STR1## and the other variables are as defined herein, and are indicated for use in the treatment and prophylaxis of, for example, hypertension, congestive heart failure, ocular hypertension, renal failure, and CNS disorders, or are intermediates the |
| 5571813 |
Fused pyrimidine compounds and their use as pharmaceuticals |
November 5, 1996 |
| Pharmaceutical compounds which are azolo-fused pyrimidine compounds having the formula ##STR1## in which .dbd.A--B-- together with the pyrimidine ring forms a) a pyrazolo[1,5-a]pyrimidine of formula (A), ##STR2## b) a [1,2,4]triazolo[1,5-a]pyrimidine of formula (B), ##STR |
| 5545636 |
Protein kinase C inhibitors |
August 13, 1996 |
| The present invention discloses compounds of the general formula: ##STR1## The compounds are highly isozyme selective protein kinase C beta-1 and beta-2 isozyme inhibitors. Accordingly, the present invention provides a method of selectively inhibiting protein kinase C isozymes beta-1 |
|
|
|
